Login to your account

Username *
Password *
Remember Me
RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

Bibliographie
3 mai 2021

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Invited commentary: Tocilizumab in COVID-19: some clarity amid controversy – The Lancet  

The post RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes appeared first on Links Medicus.

Lu 708 fois
Évaluer cet élément
(0 Votes)
Plus dans cette catégorie : « Household COVID-19 risk and in-person schooling – “While in-person schooling is associated with household COVID-19 risk, this risk can likely be controlled with properly implemented school-based mitigation measures” M-A: Tocilizumab reduces the need for mechanical ventilation in COVID-19 patients, but the randomized trials included in the analysis showed it has no significant effect on the risk of mortality or adverse events »

About Author

Zouhair Souissi

Dernier de Zouhair Souissi

Retour en haut

Recherche

Search